Smoking Cessation, Tobacco Use Cessation
Conditions
Keywords
smoking, cessation, tobacco
Brief summary
The primary study objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are to assess the: craving for cigarettes, nicotine withdrawal symptoms, and safety of dianicline.
Interventions
DRUGSSR591813L (dianicline)
Sponsors
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Outpatients, over legal age, smoking at least 10 cigarettes/day as a mean within the 2 months preceding the screening visit.
Exclusion criteria
* Patients who have taken an investigational drug within the past six months prior to the screening visit. * Patients who had a previous quit attempt (= or \>1 day with the aid of pharmacological adjunct) in the previous three months (before screening). * Patients who have smoked or consumed non-tobacco cigarettes or any form of tobacco product (other than cigarettes such as cigars, pipes, smokeless tobacco, etc) more than 3 times within the 3 months preceding the screening visit. * Patients who currently present with (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition \[DSM-IV\]): * Psychotic disorder * Major depressive episode * Pregnant or breast-feeding women. * Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy. Medically acceptable methods of birth control for this study include approved hormonal contraceptive medications or devices, approved intra-uterine contraceptive devices, use of two combined barrier methods. * Patients who have suffered from a myocardial infarction, unstable angina or other major cardiovascular event within the past week prior to screening. * Patients who have a history of multiple allergic reactions to medications in two drug classes. * Patients who have QTcF \> 500 ms on the electrocardiogram (ECG). * Patients with mild, moderate or severe renal impairment. * Patients who have an abnormal laboratory test of potential clinical significance at screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the continuous abstinence from tobacco smoking at every visit during the last 4 weeks of treatment period, i.e. from week 4 to week 7, through direct inquiry of patients, exhaled carbon monoxide (CO) testing, and plasma cotinine measurements | — |
Secondary
| Measure | Time frame |
|---|---|
| Questionnaire of Smoking Urges to assess craving for cigarettes; Hughes and Hatsukami Minnesota Withdrawal Scale to measure nicotine withdrawal, number of smoke-free days, and average number of cigarettes smoked from smoking status interview | — |
Countries
Canada, United States
Outcome results
None listed